Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

The primary objective is to assess the efficacy of EP-104GI in improving tissue health, as measured by the Eosinophilic Esophagitis Histology Scoring System (“EoEHSS”).

After six months, eligible patients initially dosed with placebo may elect to receive EP-104GI. The primary objective is to assess the efficacy of EP-104GI in improving tissue health, as measured by ...

Conclusions EoE is a chronic esophageal inflammatory disease of undetermined pathology and physiology. In childhood, vague symptoms associated with GERD and feeding difficulties are the first ...

They correlated the presence of esophageal eosinophilia (>1 eosinophil/high power field [HPF]) with markers of reflux esophagitis (abnormal pH studies, manometry and endoscopy) in 46 children.

Eosinophilic gastrointestinal diseases are exponentially more prevalent among patients with atopic diseases compared with the ...

To know more about Eosinophilic Esophagitis companies working in the treatment market, visit @ Eosinophilic Esophagitis Clinical Trials and FDA Approvals Table of Contents ...

Eosinophilic Esophagitis: Empowering Clinicians for Better Patient Outcomes This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

The primary objective is to assess the efficacy of EP-104GI in improving tissue health, as measured by the Eosinophilic Esophagitis Histology Scoring System (“EoEHSS”).

A study published in July 2025 issue of Journal of Allergy and Clinical Immunology Global highlighted persistent challenges ...